셀트리온, 1분기 영업익 3219억…1000억 규모 자사주 소각

Celltrion's significant year-over-year earnings growth demonstrates its strengthening position in the global biopharmaceutical market despite a slight quarterly dip. The aggressive stock cancellation strategy highlights a strong commitment to shareholder value, setting a benchmark for corporate governance in the Korean biotech sector.